On April 23, 2025 Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule oncology approaches with immunotherapeutic effects, reported it will present preliminary data from the Phase 2 study of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s Annual Meeting (Press release, Promontory Therapeutics, APR 23, 2025, View Source [SID1234653231]). ASCO (Free ASCO Whitepaper) 2025 will be held from May 30 – June 3, 2025 in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation will include results from the randomized Phase 2 proof of concept and dose optimization study, including safety and efficacy data from the three dosing arms, along with biomarker responses and correlative research.

Poster Session Details

Title: Preliminary phase 2 results of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC)

Location: Hall A, McCormick Place Convention Center, Chicago, Illinois
Poster Board Number: 270
Published Abstract Number: 5071

Session: Genitourinary Cancer – Prostate, Testicular, and Penile
Session date + time: June 2, 2025, 9:00 AM-12:00 PM CDT

For more information about Promontory Therapeutics and PT-112, visit www.PromontoryTx.com.